Cidara Therapeutics, Inc. (CDTX) earnings
CDTX earnings moved a median of -0.13% by the close. Quarterly and annual CDTX reports and results, each read against the price at its own news timestamp. Back to the CDTX overview →
20 measured CDTX earnings events.
Where these CDTX earnings landedvs 20 measured CDTX earnings reactions
| Middle 50% of CDTX earnings reactions | -4.87% to +6.21% |
|---|---|
| Median reaction (to close) | -0.13% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 CDTX earnings events with a measured close landed between -4.87% and +6.21%; 50% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Press release | +4.75% | +6.21% | |
| Form 10-Q Cidara Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +4.75% | +6.21% | |
| Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025 | Press release | -0.25% | -4.73% | |
| Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | Press release | +4.71% | +7.29% | |
| Form 10-Q Cidara Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +4.71% | +7.29% | |
| Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 | Press release | -2.21% | -2.33% | |
| Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results | Press release | -4.08% | -11.16% | |
| Form 10-Q Cidara Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -4.08% | -11.16% | |
| Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025 | Press release | +0.32% | -1.92% | |
| Form 10-K Cidara Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +1.19% | +8.28% | |
| Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results | Press release | +0.07% | +1.66% | |
| Form 10-Q Cidara Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.07% | +1.66% | |
| Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results | Press release | -0.40% | +2.55% | |
| Form 10-Q Cidara Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -0.40% | +2.55% | |
| Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results | Press release | +0.73% | -2.28% | |
| Form 10-Q Cidara Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.73% | -2.28% | |
| Form 10-K Cidara Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.81% | -5.30% | |
| Form NT 10-K Cidara Therapeutics, For: Dec 31 | SEC filing · Form NT | -1.24% | +19.48% | |
| Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results | Press release | -1.12% | -8.99% | |
| Form 10-Q Cidara Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -1.12% | -8.99% |
Keep exploring
More CDTX: analyst actions → · SEC filings → · CDTX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Brookdale Senior Living Inc. (BKD) | 341 | +0.36% | 62% |
| Vaxart, Inc. (VXRT) | 341 | -0.81% | 41% |
| DaVita Inc. (DVA) | 339 | +0.07% | 53% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 339 | +0.29% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.